What We Know So Far About the Different Strains of COVID-19

Introduction to COVID-19 Strains

Since the onset of the COVID-19 pandemic, various strains of the virus have emerged, each with distinct characteristics. Understanding these variants is crucial for effective prevention and treatment strategies. In this article, we delve into what we know so far about the different strains of COVID-19.

The Original Strain: Wuhan-Hu-1

The original strain of SARS-CoV-2, known as Wuhan-Hu-1, was first identified in Wuhan, China, in late 2019. This strain quickly spread globally, leading to the pandemic declaration by the World Health Organization (WHO) in March 2020.

Alpha Variant (B.1.1.7)

First detected in the United Kingdom in September 2020, the Alpha variant is known for its increased transmissibility. Research indicates that the Alpha variant may be up to 50% more contagious than the original strain, contributing to rapid spread in many regions.

Beta Variant (B.1.351)

Identified in South Africa in May 2020, the Beta variant has mutations that may help it evade some of the immune responses generated by previous infection or vaccination. This has raised concerns about vaccine efficacy against this variant.

Gamma Variant (P.1)

The Gamma variant was first reported in Brazil in November 2020. Similar to the Beta variant, it carries mutations that might lead to increased transmissibility and potential resistance to neutralizing antibodies.

Delta Variant (B.1.617.2)

First identified in India in October 2020, the Delta variant quickly became the dominant strain in many countries due to its high transmissibility. Studies suggest that the Delta variant could be up to 60% more transmissible than the Alpha variant.

Omicron Variant (B.1.1.529)

The Omicron variant, identified in South Africa in November 2021, has numerous mutations in the spike protein. Early data indicated that Omicron could spread more easily than previous variants, though its severity and impact on vaccine efficacy were still being studied.

Preventive Measures and Future Outlook

Despite the emergence of various strains, preventive measures such as vaccination, mask-wearing, and social distancing remain effective. Ongoing research and adaptation of vaccines will be crucial in managing the virus’s evolution.

The Transition from Omicron to Sub-variant Lineages: BA.2, BA.5, and XBB

While the initial emergence of the Omicron variant (B.1.1.529) marked a significant shift in the pandemic, the subsequent diversification of this lineage into various sub-variants has defined the viral landscape for several years. Unlike previous transitions between distinct variants of concern—such as the jump from Delta to Omicron—recent evolution has been characterized by a gradual accumulation of mutations within the Omicron family tree. The BA.2 sub-variant, often referred to as “Stealth Omicron,” gained prominence in early 2022 because it lacked the S-gene target failure (SGTF) signature that allowed researchers to easily distinguish BA.1 from Delta using standard PCR tests. This necessitated a shift toward more comprehensive genomic sequencing to track its spread accurately.

Following BA.2, the BA.4 and BA.5 sub-variants emerged, notable for their identical spike proteins but differing mutations in other parts of the viral genome. These strains were particularly adept at evading the immunity conferred by earlier Omicron infections. The L452R mutation, previously seen in the Delta variant, reappeared in BA.5, enhancing its ability to bind to human ACE2 receptors and potentially increasing its fusogenicity—the ability of the virus to fuse cells together. This period marked the beginning of a cycle where new sub-variants emerged every few months, each possessing a slight growth advantage over its predecessor through a combination of increased transmissibility and immune evasion.

By late 2022 and early 2023, the XBB lineage, a recombinant of two different BA.2 descendants, began to dominate. XBB.1.5, nicknamed “Kraken,” featured a critical F486P mutation. This specific change was a masterclass in viral adaptation: it allowed the virus to maintain high immune evasion while simultaneously restoring the binding affinity to the ACE2 receptor that had been slightly compromised in previous iterations. The rapid takeover of XBB.1.5 demonstrated that the virus was no longer just escaping antibodies but was actively refining its entry mechanisms to remain highly infectious even in populations with high levels of pre-existing immunity.

Convergent Evolution and the Rise of “FLiRT” Mutations

One of the most fascinating aspects of SARS-CoV-2 evolution is the phenomenon of convergent evolution, where unrelated sub-lineages independently develop the same mutations to solve the same “problems.” As the virus faced intense pressure from global immunity—derived from both vaccinations and natural infections—different branches of the Omicron tree began to converge on a specific set of mutations in the spike protein. This trend became most apparent with the emergence of the JN.1 variant and the subsequent “FLiRT” variants (a name derived from the technical names of their mutations, such as F456L and R346T).

The JN.1 variant, which descended from BA.2.86 (Pirola), represented a massive evolutionary leap. It contained over 30 mutations in the spike protein compared to its predecessors. One of the most significant was the L455S mutation, which significantly enhanced its ability to evade neutralizing antibodies. The “FLiRT” variants that followed JN.1 continued this trend, fine-tuning the balance between immune escape and ACE2 binding. These mutations specifically target the class 1 and class 2 neutralizing antibody sites, which are the primary targets of the antibodies generated by current vaccines and previous infections.

This convergent evolution suggests that the virus may be reaching a “fitness peak” in its current environment. By observing these patterns, scientists can now predict with greater accuracy which mutations are likely to appear next. For instance, the transition from a phenylalanine (F) to a leucine (L) at position 456 has occurred repeatedly across different lineages, indicating that this specific change provides a significant survival advantage. Understanding these molecular patterns is essential for the development of future-proof vaccines that target the most stable regions of the spike protein or anticipate these common mutational shifts.

Differential Pathophysiology and Symptom Evolution Across Strains

As the virus has mutated, the clinical presentation of COVID-19 has undergone a noticeable transformation. The original Wuhan strain and the subsequent Alpha and Delta variants were primarily associated with lower respiratory tract infections, often leading to viral pneumonia and severe lung damage. Common symptoms included a persistent dry cough, high fever, and the hallmark loss of taste and smell (anosmia and ageusia). These strains had a high affinity for the TMPRSS2 protein, an enzyme found abundantly in lung tissue that facilitates viral entry into cells.

With the advent of the Omicron lineage, the virus’s preferred route of entry shifted. Omicron and its descendants tend to utilize the endosomal pathway more efficiently, which is more common in the upper respiratory tract. Consequently, the symptoms shifted toward those resembling an upper respiratory infection: severe sore throat, nasal congestion, headache, and fatigue. The loss of taste and smell became significantly less common, occurring in less than 20% of cases compared to over 60% during the Delta wave. This shift in pathophysiology explains why Omicron, while more transmissible, generally resulted in lower rates of severe pneumonia and mechanical ventilation in vaccinated populations.

Furthermore, the incubation period has shortened significantly as the virus has evolved. The original strain had an average incubation period of about 5.2 days, which shortened to 4.4 days for Delta and approximately 3 days for Omicron. This rapid onset of symptoms contributes to the difficulty of containing outbreaks, as individuals become infectious much sooner after exposure. In pediatric populations, later Omicron sub-variants have been associated with an increase in croup-like symptoms—a barking cough caused by upper airway inflammation—which was less frequently observed with earlier strains. These changes highlight the necessity for clinicians to remain flexible in their diagnostic criteria as new strains emerge.

Genomic Surveillance and the Science of Wastewater Tracking

As clinical testing has shifted from centralized PCR facilities to home-based rapid antigen tests, traditional methods of tracking COVID-19 strains have become less comprehensive. To fill this gap, genomic surveillance has evolved to include innovative techniques, most notably wastewater-based epidemiology (WBE). By sequencing the viral RNA found in municipal sewage, public health officials can detect the presence of specific variants in a community up to two weeks before they appear in clinical diagnostic reports. This provides a crucial early warning system for the arrival of new strains.

Wastewater tracking allows for the identification of “cryptic lineages”—variants that may be circulating in a population but have not yet been captured by clinical sequencing. In some instances, researchers have identified highly mutated sequences in specific sewer sheds that do not match any known global variants. These are often hypothesized to originate from single individuals with chronic infections or from local animal reservoirs. The ability to monitor the viral load in wastewater also provides a more objective measure of community transmission levels, as it is not biased by healthcare-seeking behavior or the availability of testing kits.

The technical process involves concentrating the virus from large volumes of water, extracting the RNA, and performing deep sequencing. Because wastewater contains a mixture of many different viral genomes from thousands of people, bioinformaticians must use complex algorithms to “deconvolve” the data and determine the relative proportions of different variants. This high-resolution data is now a cornerstone of the WHO’s global surveillance strategy, allowing for the real-time monitoring of how a new sub-variant like JN.1 displaces older lineages across different geographic regions.

The Role of Recombination in Viral Diversification

While most viral evolution occurs through small, stepwise mutations (antigenic drift), SARS-CoV-2 is also capable of larger evolutionary jumps through a process called recombination. This occurs when a single host cell is simultaneously infected with two different strains of the virus. During the replication process, the viral polymerase enzyme can “jump” from one RNA template to another, creating a hybrid genome that contains genetic material from both parent strains. This can result in a new variant that possesses the most advantageous traits of both predecessors.

The XBB lineage is the most prominent example of a successful recombinant. It emerged from a recombination event between two different sub-lineages of BA.2: BJ.1 and BM.1.1.1. By combining the mutations from these two distinct branches, XBB achieved a level of immune evasion that neither parent could have attained through simple mutation alone. Other recombinants, such as “Deltacron” (a hybrid of Delta and Omicron), were identified early in 2022 but failed to gain a foothold because they did not offer a significant fitness advantage over the dominant Omicron strains.

Recombination poses a unique challenge for vaccine design because it can lead to sudden and unpredictable changes in the virus’s behavior. If a highly pathogenic but less transmissible strain (like a hypothetical MERS-like variant) were to recombine with a highly transmissible strain like Omicron, the resulting hybrid could be devastating. Monitoring for these recombination events requires constant vigilant sequencing of samples from around the world, particularly in regions where multiple variants are co-circulating at high levels. The discovery of these “chimera” viruses underscores the complexity of the virus’s evolutionary trajectory.

Chronic Infections in Immunocompromised Hosts as Evolutionary Incubators

A growing body of evidence suggests that some of the most highly mutated variants of COVID-19 do not emerge through gradual transmission from person to person, but rather within a single individual over a long period. In immunocompromised patients—such as those undergoing chemotherapy or living with advanced HIV—the immune system may be unable to clear the virus, but strong enough to exert “selection pressure.” This creates an environment where the virus can persist for months, constantly mutating to evade the patient’s weakening immune response.

Studies of these chronic infections have shown that the virus can accumulate as many mutations in a single patient over six months as it would normally accumulate in the general population over several years. Many of the mutations seen in the original Omicron variant were first observed in sequences taken from chronically infected individuals. These patients essentially act as “evolutionary incubators,” allowing the virus to test out various combinations of mutations in a high-stakes environment. When one of these highly evolved strains eventually jumps back into the general population, it can appear as a “saltational” event—a sudden leap in evolution that seems to come out of nowhere.

This phenomenon highlights a critical public health priority: protecting and treating immunocompromised individuals is not only a matter of individual patient care but also a vital strategy for preventing the emergence of the next major variant. By using aggressive antiviral therapies and monoclonal antibodies to clear persistent infections, clinicians can reduce the likelihood that these patients will inadvertently host the next significant evolutionary leap of the virus.

Therapeutic Challenges and the Evolving Efficacy of Antivirals

The continuous evolution of COVID-19 strains has had a profound impact on our therapeutic toolkit. Most notably, the efficacy of monoclonal antibody (mAb) treatments has been severely compromised by the virus’s changing spike protein. Early in the pandemic, treatments like Bamlanivimab and the REGEN-COV cocktail were highly effective at neutralizing the virus. However, as the Alpha, Delta, and eventually Omicron variants emerged, these antibodies lost their ability to bind to the mutated spike protein. By the time the XBB and JN.1 lineages became dominant, almost all previously authorized monoclonal antibodies were rendered ineffective, leading to their withdrawal from clinical use.

In contrast, small-molecule antiviral drugs like Paxlovid (nirmatrelvir/ritonavir) and Molnupiravir have remained largely effective across different strains. This is because these drugs do not target the highly variable spike protein. Instead, Paxlovid targets the 3CL protease, an enzyme the virus needs for replication that has remained remarkably stable throughout the pandemic. While researchers have identified some mutations that could potentially lead to Paxlovid resistance, these have not yet become widespread in the global population. This stability makes protease inhibitors a more reliable long-term strategy against an evolving virus.

The evolution of the virus also necessitates the periodic updating of vaccine formulations. The shift from monovalent vaccines (targeting the original strain) to bivalent vaccines (targeting both the original and BA.4/BA.5) and then to XBB.1.5-specific vaccines reflects this ongoing arms race. Each update aims to “re-train” the immune system to recognize the most current version of the spike protein. However, the phenomenon of “antigenic imprinting”—where the immune system’s response is biased by its first exposure to the virus—remains a challenge. Researchers are currently exploring “pan-coronavirus” vaccines that target more conserved regions of the virus to provide broader protection that doesn’t disappear every time a new sub-variant emerges.

FAQ

Q1: How do COVID-19 variants arise?
A1: Variants arise through mutations in the virus’s genetic code, which occur during replication. Some mutations can lead to increased transmissibility or resistance to immunity.
Q2: Are current vaccines effective against all strains?
A2: While vaccines remain effective at preventing severe illness and death, their efficacy against mild or asymptomatic infection may vary with different strains.
Q3: Can I get infected with multiple COVID-19 variants?
A3: Yes, it is possible to be infected with different variants over time, especially if immunity wanes or if a variant can evade existing immunity.
Q4: What is the most concerning COVID-19 variant?
A4: The most concerning variant can change over time. Currently, the Delta and Omicron variants have been of significant concern due to their high transmissibility.
Q5: How can we protect ourselves from new variants?
A5: Vaccination, booster doses, wearing masks, practicing good hygiene, and following public health guidelines help protect against new variants.